CD38 and angioimmunoblastic T-cell lymphoma: Recently, Zaja et al. documented that approximately 80% of AITL and 60% of PTCL-NOS express variable levels of CD38, respectively [76], thus providing a rationale for anti-CD38 antibodies in this setting.